Search Result

Results for "

CP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (17) Acetyl-CoA Carboxylase (3) Acyltransferase (1) Adenosine Receptor (2) Adenylate Cyclase (1) Adrenergic Receptor (1) Aldehyde Dehydrogenase (ALDH) (1) Aldose Reductase (1) Amino Acid Decarboxylase (1) Antibiotic (29) APC (2) Apoptosis (22) ATM/ATR (1) Autophagy (23) Bacterial (33) BCRP (1) Beta-lactamase (3) Biochemical Assay Reagents (7) Calcium Channel (7) Cannabinoid Receptor (9) CCR (2) CDK (4) CETP (3) CFTR (2) Cholinesterase (ChE) (1) Complement System (6) COX (10) CRFR (4) CTLA-4 (1) CXCR (1) Cytochrome P450 (10) DNA/RNA Synthesis (2) Dopamine Receptor (9) Drug Derivative (3) Drug Metabolite (5) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (2) EGFR (12) Endogenous Metabolite (1) ERK (2) Estrogen Receptor/ERR (2) Farnesyl Transferase (2) Ferroptosis (1) FGFR (3) Filovirus (1) FLT3 (2) Fluorescent Dye (3) Fungal (3) G Protein-coupled Receptor Kinase (GRK) (1) GABA Receptor (2) GHSR (2) Glucocorticoid Receptor (2) GSK-3 (1) HCV Protease (2) Herbicide (1) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (5) HSP (2) IFNAR (3) IGF-1R (1) iGluR (8) Influenza Virus (2) Interleukin Related (1) Isotope-Labeled Compounds (31) JAK (11) JNK (1) Leukotriene Receptor (6) Ligands for Target Protein for PROTAC (3) Liposome (7) mAChR (1) MAP3K (1) MDM-2/p53 (2) Microsomal Triglyceride Transfer Protein (MTP) (4) Microtubule/Tubulin (2) Mitophagy (2) Mitosis (1) MMP (5) Monoamine Oxidase (1) Na+/H+ Exchanger (NHE) (6) nAChR (19) Neurokinin Receptor (3) NF-κB (4) NO Synthase (3) NOD-like Receptor (NLR) (3) Nucleoside Antimetabolite/Analog (3) Opioid Receptor (2) P-glycoprotein (9) p38 MAPK (2) Parasite (4) PDGFR (3) Phosphodiesterase (PDE) (3) Phosphorylase (3) Phytohormone (1) PKC (1) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (5) PPAR (4) Prostaglandin Receptor (4) PROTAC Linkers (1) PROTACs (5) Ras (1) Reactive Oxygen Species (1) Reference Standards (7) Renin (2) SARS-CoV (6) Small Interfering RNA (siRNA) (3) STAT (1) TMV (4) TNF Receptor (1) Topoisomerase (3) Tryptophan Hydroxylase (2) VEGFR (4) Virus Protease (1)
By Research Areas:	Cancer (117) Cardiovascular Disease (22) Endocrinology (16) Infection (49) Inflammation/Immunology (76) Metabolic Disease (30) Neurological Disease (83)
Click Chemistry:	PROTAC Synthesis (1) Azide (2) Alkynes (12)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

334

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Connective Peptide

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13525

CP-91149 5+ Cited Publications	Biochemical Assay Reagents	Metabolic Disease Cancer
CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study .

HY-105445

CP-113818 2 Publications Verification	Acyltransferase	Neurological Disease
CP-113818 is a potent cholesterol acyltransferase (ACAT) inhibitor. CP-113818 can be used for the research of Alzheimer's disease .

HY-123039

CP-532623	CETP	Metabolic Disease
CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties .

HY-18228

CP-352664	JAK	Inflammation/Immunology
CP-352664 is a JAK inhibitor. CP-352664 has a inhibitoinhibits JAK3 with an EC₅₀ value of 210 nM. CP-352664 is promising for research of organ transplant rejection and autoimmune disorders such as rheumatoid arthritis .

HY-113642

CP-67804	Topoisomerase	Cancer
CP-67804 is a quinolone derivative, is a topoisomerase II-targeted agent. CP-67804 effectively enhances DNA cleavage mediated by eukaryotic topoisomerase II. CP-67804 has potential as an antineoplastic agent .

HY-101357AR

CP 93129 dihydrochloride (Standard)	Reference Standards 5-HT Receptor	Neurological Disease
CP 93129 (dihydrochloride) (Standard) is the analytical standard of CP 93129 (dihydrochloride). This product is intended for research and analytical applications. CP 93129 dihydrochloride is a potent 5HT1B receptor agonist. CP 93129 dihydrochloride has the potential for parkinson's disease research .

HY-111129

CP-66713	Adenosine Receptor	Neurological Disease
CP-66713 is a selective adenosine A2 receptor antagonist, with K_i of 22 nM. CP-66713 inhibits induction of long-term potentiation of evoked synaptic potentials. CP-66713 can be used in the study of neurological diseases .

HY-149769

CP-506	Cytochrome P450	Cancer
CP-506 (compound 26) is an anticancer compound and a substrate for nitroreductase and CYP oxidoreductases. CP-506 has anticancer activity .

HY-149769A

CP-506 mesylate	Cytochrome P450	Cancer
CP-506 (compound 26) mesylate is an anticancer compound and a substrate for nitroreductase and CYP oxidoreductases. CP-506 has anticancer activity .

HY-16946

CP-610431	Acetyl-CoA Carboxylase	Metabolic Disease
CP-610431 is a reversible, ATP-uncompetitive, isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor. CP-610431 inhibits ACC1 and ACC2 with IC₅₀s of ~50 nM. CP-610431 can be used for the research of metabolic syndrome .

HY-149495

CP-07	PROTACs CDK	Cancer
CP-07 is a potent and selective PROTACCDK9 degrader (DC₅₀: 43 nM). CP-07 inhibits 22RV1 cell proliferation (IC₅₀: 62 nM) and colony formation by down-regulating Mcl-1 and c-Myc. CP-07 inhibits 22RV1 xenograft tumor growth. CP-07 can be used for research of prostate cancer .

HY-112199

CP-447697	Complement System	Inflammation/Immunology
CP-447697 is a lipophilic C5a receptor antagonist with an IC₅₀ value of 31 nM. CP-447697 can be used for the research of inflammation .

HY-123203

CP-608039	Adenosine Receptor	Cardiovascular Disease
CP-608039 is a potent and selective adenosine A3 receptor agonist. CP-608039 can be used for ischemic myocardial injury research .

HY-171476

CP-865569	CCR	Inflammation/Immunology
CP-865569 is a CCR1 antagonist. CP-865569 can be used in the research of inflammatory diseases and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis .

HY-124815

CP-312	Reactive Oxygen Species	Others
CP-312 is a potent Heme Oxygenase-1 (HO-1) inducer. CP-312 protects hiPSC-CM viability by targeting the antioxidant response network through induction of HMOX1 expression. CP-312 protects human iPSC-derived cardiomyocytes from oxidative stress .

HY-18663B

CP-465022 hydrochloride	iGluR	Neurological Disease
CP-465022 hydrochloride is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-18663

CP-465022	iGluR	Neurological Disease
CP-465022 is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-18663A

CP-465022 maleate	iGluR	Neurological Disease
CP-465022 Maleate is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-10049

CP 122721	Neurokinin Receptor	Neurological Disease Inflammation/Immunology
CP 122721 is an orally active NK1 receptor antagonist. CP 122721 attenuates cisplatin-induced vomiting in ferrets (ID₅₀: 0.08 mg/kg). CP 122721 inhibits kainate (KA)-induced seizure activity and CA1 neuronal cell death in rats. CP 122721 is useful in the study of depression, asthma, and irritable bowel syndrome (IBS) .

HY-13302

CP-547632 1 Publications Verification	VEGFR FGFR	Cancer
CP-547632 is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy .

HY-13302B

CP-547632 hydrochloride 1 Publications Verification	VEGFR FGFR	Cancer
CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy .

HY-120076

CP-293019	Dopamine Receptor	Neurological Disease
CP-293019 is a dopamine D4 receptor antagonist, with a K_i value of 3.4 nM. CP-293019 can inhibit Apomorphine (HY-12723) induced hyperactivity in rats .

HY-109855

CP-67015	Topoisomerase Antibiotic Bacterial	Infection
CP-67015, a quinolone antibiotic, is a potent topoisomerase II inhibitor. CP-67015 is a positive direct-acting mutagen in mammalian cells with both gene and chromosomal level effects .

HY-101357A

CP 93129 dihydrochloride	5-HT Receptor	Neurological Disease
CP 93129 dihydrochloride is a potent 5HT_1B receptor agonist. CP 93129 dihydrochloride has the potential for parkinson's disease research .

HY-12145

CP-99994 hydrochloride	Endogenous Metabolite	Neurological Disease
CP-99994 hydrochloride is a high-affinity NK1 antagonist that exhibits the biological activity of preventing colorectal sensitization in the context of visceral hypersensitivity. CP-99994 hydrochloride reduces colorectal hypersensitivity induced by acetic acid injections in a model of bladder-colon cross-sensitization. CP-99994 hydrochloride attenuates the neuroglial interactions and MAPK-p38 phosphorylation associated with visceral hypersensitivity.

HY-12079

CP-481715	CCR	Inflammation/Immunology
CP-481715 is a potent, reversible and selective CCR1 antagonist with a K_d of 9.2 nM for human CCR1. CP-481715 is >100-fold selective for CCR1 as compared with a panel of G-protein-coupled receptors including related chemokine receptors. CP-481715 has the potential for rheumatoid arthritis and other inflammatory diseases research .

HY-14674

CP-724714 4 Publications Verification	EGFR Apoptosis	Cancer
CP-724714 is a potent, selective and orally active ErbB2 (HER2) tyrosine kinase inhibitor, with an IC₅₀ of 10 nM. CP-724714 displays a marked selectivity against EGFR kinase (IC₅₀=6400 nM). CP-724714 potently inhibits ErbB2 receptor autophosphorylation in intact cells. Antitumor activities .

HY-U00008

CP-28888 CP 28888-27	IFNAR	Infection
CP-28888 is an interferon inducer, more potent in mice, but is less active in man and devoid of antirhinovirus effects.

HY-12129

CP 154526 hydrochloride	CFTR	Neurological Disease
CP 154526 hydrochloride is a potent, brain-penetrant and selective corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i of 2.7 nM. CP 154526 hydrochloride shows selective for CRF1 over CRF2 (K_i = >10 μM). CP 154526 hydrochloride has anxiolytic activities .

HY-12130

CP 154526	CRFR	Neurological Disease
CP 154526 is a potent, brain-penetrant and selective corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i of 2.7 nM. CP 154526 shows selective for CRF1 over CRF2 (K_i = >10 μM). CP 154526 has anxiolytic activities .

HY-107634

CP-20961 Avridine	IFNAR	Infection Inflammation/Immunology
CP-20961 is an interferon inducer. CP-20961 is a potent synthetic non-immunogenic adjuvant that induces arthritis .

HY-P2024

CP-85339	Renin	Cardiovascular Disease
CP-85339 is a tetrapeptide renin inhibitor .

HY-112742

CP-195543	Leukotriene Receptor	Inflammation/Immunology
CP-195543 is a potent, selective and orally active leukotriene B4 (LTB4) receptor antagonist with IC₅₀s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration .

HY-129785

CP-220629	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology
CP-220629 is a potent inhibitor of PDE4, with the IC₅₀ of 0.44 μM. CP-220629 is efficacious in the guinea pig aerosolized antigen induced airway obstruction assay (ED₅₀ 2.0 mg/kg) .

HY-113955

CP-346086	Microsomal Triglyceride Transfer Protein (MTP)	Metabolic Disease
CP-346086 is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC₅₀ of 2.0 nM for human and rodent MTP. CP-346086 can lower plasma cholesterol and triglycerides in vivo .

HY-138879B

CP-601932 (1S,5R)-CP-601927	nAChR	Neurological Disease
CP-601932 ((1S,5R)-CP-601927) is a high-affinity partial agonist at α3β4 nAChR (K_i=21 nM; EC₅₀=~ 3 μM). CP-601932 has the same high-binding affinity at α4β2 nAChR (K_i=21 nM) and an order of magnitude lower affinity for α6 and α7 nAChR subtypes. CP-601932 selectively decreases ethanol but not sucrose consumption and operant self-administration following long-term exposure. CP-601932 can penetrate the CNS .

HY-123289

CP-690550A	JAK	Inflammation/Immunology
CP-690550A is an analogue of Tofacitinib (HY-40354). CP-690550A is a dual inhibitor of JAK2 and JAK3 .

HY-108482

CP-96,345	Neurokinin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
CP-96,345 is a specific, highly potent, and orally active tachykinin and substance P receptor non-peptide inhibitor. CP-96,345 prevents the drop in blood pressure evoked by substance P and neurokinin A. CP-96,345 can be used for researching neurogenic inflammation .

HY-14941

Elacytarabine CP 4055	Nucleoside Antimetabolite/Analog	Cancer
Elacytarabine (CP 4055) is a lipid-conjugated derivative of the nucleoside analog cytarabine. Elacytarabine (CP 4055) is an antineoplastic agent with cytotoxicity in solid tumors.

HY-101357

CP 93129	5-HT Receptor	Neurological Disease
CP 93129 is a potent and selective 5-HT_1B agonist. CP 93129 has the potential for the research of Parkinson's disease .

HY-103092

CP-135807	5-HT Receptor	Neurological Disease
CP-135807 is an orally active and selective 5-HT1D agonist (IC₅₀=3.1 nM), bovine). CP-135807 mediates central psychoactivity and can be used in antidepressant research .

HY-108571

CP-775146	PPAR	Metabolic Disease
CP-775146 is a selective PPARα agonist that binds strongly to the PPARα ligand. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway .

HY-18343

CP-31398	MDM-2/p53 Apoptosis	Cancer
CP-31398 can stabilize the active conformation of p53 and promote p53 activity in cancer cells with either mutant or wild-type p53. In addition, CP-31398 can upregulate p53 target genes, such as p21WAF1/Cip1 and KILLER/DR5. CP-31398 exerts an inhibitory effect on tumor growth .

HY-150082

CP681301	CDK DNA/RNA Synthesis	Cancer
CP681301 is a potent CDK5 inhibitor. CP681301 shows antiproliferative activity. CP681301 decreases the expression of CD133, OLIG2, SOX2, KI67, pCDK5 protein level in GSCs (Glioma stem cells). CP681301 reduces self-renewal in mouse glioma xenografts. CP681301 shows anti-tumor activity in Drosophila .

HY-13302C

CP-547632 TFA	VEGFR FGFR	Cancer
CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy .

HY-123582

CP-866,087	Opioid Receptor	Neurological Disease
CP-866,087 is a novel, potent and selective μ-opioid receptor antagonist with activity to inhibit opioid effects. CP-866,087 has shown promising preclinical efficacy data in disease models associated with alcohol consumption. CP-866,087 has also been used to study female sexual dysfunction .

HY-16372

CP 461 OSI-461	Apoptosis Microtubule/Tubulin	Cancer
CP-461 (OSI-461) is a selective apoptotic antineoplastic drug (SAAND) by engaging tubulin on colchicine site

HY-119721

CP-424174	NOD-like Receptor (NLR)	Inflammation/Immunology
CP-424174 is a reversible inhibitor against IL-1β processing with an IC₅₀ of 210 nM.CP-424174 indirectly inhibits NLRP3 .

HY-101639A

CP-409092 hydrochloride	GABA Receptor	Neurological Disease
CP-409092 hydrochloride is a partial agonist of GABA_A receptor, with anti-anxiety activity .

HY-101639

CP-409092	GABA Receptor	Neurological Disease
CP-409092 is a partial agonist of GABA_A receptor, with anti-anxiety activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0678

Icaritin 2 Publications Verification Anhydroicaritin	Flavonols Structural Classification Classification of Application Fields Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Phenols Polyphenols Epimedium brevicornu Maxim. Berberidaceae Disease Research Fields Cancer	JAK Autophagy Apoptosis
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis ^[3.

HY-113421

Linoleoyl ethanolamide Linoleic acid monoethanolamide	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Cannabinoid Receptor
Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

HY-107233

Saponin CP4 Prosapogenin CP4	Triterpenes Classification of Application Fields Terpenoids Source classification Ranunculaceae Other Diseases Plants Clematis grandidentata (Rehder & E. H. Wilson) W. T. Wang Disease Research Fields	Others
Saponin CP4 is an oleanolic acid derivative which lacks a 23-OH. Saponin CP4 shows no growth inhibition .

HY-107235

Saponin CP6 Clematoside S; Prosapogenin CP6	Triterpenes Classification of Application Fields Terpenoids Source classification Ranunculaceae Other Diseases Plants Disease Research Fields Clematis grata Wall.	Others
Saponin CP6 is a triterpenoid compound from the roots of Clematis grata .

HY-N10268

3-Hydroxyterphenyllin NSC 299113	Microorganisms Classification of Application Fields Source classification Phenols Polyphenols Disease Research Fields Cancer	Apoptosis
3-Hydroxyterphenyllin is a metabolite of Aspergillus candidus.3-Hydroxyterphenyllin suppresses proliferation and causes cytotoxicity against A2780/CP70 and OVCAR-3 cells. 3-Hydroxyterphenyllin induces S phase arrest and apoptosis. 3-Hydroxyterphenyllin has the potential for the research of ovarian cancer .

HY-N13047

Ningnanmycin	Structural Classification Microorganisms Antibiotics Source classification Other Antibiotics	Others
Ningnanmycin is a plant antiviral agent that has been found to directly bind to the coat protein (CP) of tobacco mosaic virus (TMV) and inhibit its assembly process. These interactions lead to the dissociation of the coat protein from the discoid structure into monomers，significantly reducing the pathogenicity of TMV .

HY-N0678R

Icaritin (Standard)	Flavonols Structural Classification Human Gut Microbiota Metabolites Flavonoids Source classification Phenols Polyphenols Epimedium brevicornu Maxim. Plants Endogenous metabolite Berberidaceae	JAK Autophagy Apoptosis
Icaritin (Standard) is the analytical standard of Icaritin. This product is intended for research and analytical applications. Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 μM) and primary CML cells (IC₅₀ of 13.4 μM for CML-CP and 18 μM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis [3.

Cat. No.	Product Name	Chemical Structure

HY-A0064S1

Verapamil-d6 hydrochloride

Verapamil-d₆ (CP-16533-1-d₆) hydrochloride is the deuterium labled Verapamil (hydrochloride) (HY-A0064). Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research .

HY-B0334S

Sulbactam-d3
Sulbactam-d₃ (CP45899-d₃) is deuterium labeled Sulbactam. Sulbactam (CP45899) is a competitive, irreversible beta-lactamase inhibitor. Sulbactam shows antimicrobial activity against multidrug-resistant (MDR) acinetobacter calcoaceticus--Acinetobacter baumannii (Acb) complex .

HY-B0253S1

Piroxicam-d4
Piroxicam-d₄ is the deuterium labeled Piroxicam. Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.

HY-50896S

Erlotinib-d6
Erlotinib-d₆ (CP-358774 D₆) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC₅₀ of 2 nM for human EGFR . Erlotinib-d6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13256AS1

Desmethyl Erlotinib-d4-1
Desmethyl Erlotinib-d₄-1 (OSI-420-d₄-1 (free base); CP-373420-d₄-1) is deuterium-labeled Desmethyl Erlotinib (HY-13256A) .

HY-50896S3

Erlotinib-d8

Erlotinib-d₈ (CP-358774-d₈) is deuterium labeled Erlotinib. Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC₅₀ of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC₅₀ of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-50896S2

Erlotinib-d4

Erlotinib-d₄ (CP-358774-d₄) is deuterium labeled Erlotinib. Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC₅₀ of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC₅₀ of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B0334AS1

Sulbactam-d2 sodium
Sulbactam-d₂ (sodium) is the deuterium labeled Sulbactam sodium . Sulbactam (CP45899) sodium is a competitive, irreversible beta-lactamase inhibitor. Sulbactam sodium shows antimicrobial activity against multidrug-resistant (MDR) acinetobacter calcoaceticus--Acinetobacter baumannii (Acb) complex .

HY-10020S

Varenicline-15N3 hydrochloride

Varenicline-15N3 Hydrochloride (CP 526555-15N3 Hydrochloride) is the ¹⁵N labeled isotope of Varenicline hydrochloride (HY-10020). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10019S

Varenicline-d4

Varenicline-d₄ is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment .

HY-12008S1

Erlotinib-13C6 hydrochloride
Erlotinib- ¹³C₆ hydrochloride is the ¹³C labeled Erlotinib Hydrochloride . Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified EGFR kinase with an IC₅₀ of 2 nM . Erlotinib- ¹³C₆ hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10019S2

Varenicline-13C15N

Varenicline- ¹³C ¹⁵N (CP 526555- ¹³C ¹⁵N) is ¹³C and ¹⁵N labeled Varenicline. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10019S1

Varenicline-15N,13C,d2

Varenicline- ¹⁵N, ¹³C,d₂ is ¹⁵N and deuterated labeled Varenicline (HY-10019). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀=250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-14542S

Ziprasidone-d8
Ziprasidone-d₈8 is deuterium labeled Ziprasidone, which is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.

HY-B0253S

Piroxicam-d3
Piroxicam-d₃ is deuterium labeled Piroxicam. Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC₅₀s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively .

HY-105028S

Tenidap-d3
Tenidap-d₃ is the deuterium labeled Tenidap. Tenidap, a non-steroidal anti-inflammatory drug, is a selective COX-1 inhibitor, with IC₅₀ values of 0.03 μM and 1.2 μM for COX-1 and COX-2, respectively. Tenidap has anti-inflammatory and antirheumatic properties . Tenidap is also a specific SLC26A3 inhibitor .

HY-B0915S

Orbifloxacin-d5 hydrochloride
Orbifloxacin-d5 (hydrochloride) is a deuterated labeled Orbifloxacin .

HY-40354S3

Tofacitinib-13C
Tofacitinib- ¹³C (Tasocitinib- ¹³C) is ¹³C labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-40354S5

Tofacitinib-d3
Tofacitinib-d₃ (Tasocitinib-d₃) is deuterium labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-15662S

Tulathromycin A-d7
Tulathromycin A-d₇ (Tulathromycin-d₇) is deuterium labeled Tulathromycin A. Tulathromycin A (Tulathromycin), a macrolide antibiotic, inhibits protein synthesis (IC₅₀=0.26 μM) by targeting bacterial ribosome. Tulathromycin A is used for the research of respiratory disease in cattle and swine. Immunomodulatory effects .

HY-A0064S

Verapamil-d3 hydrochloride
Verapamil-d₃ (hydrochloride) is the deuterium labeled Verapamil hydrochloride. Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research .

HY-14275S

Verapamil-d3
Verapamil-d₃ ((±)-Verapamil-d₃) is deuterium labeled Verapamil. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .

HY-14275S2

Verapamil-d6
Verapamil-d₆ ((±)-Verapamil-d₆) is deuterium labeled Verapamil. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .

HY-14275S1

Verapamil-d7
Verapamil-d₇ is the deuterium labeled Verapamil (HY-14275). Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .

HY-17506S1

Azithromycin-13C,d3
Azithromycin- ¹³C,d₃ is the deuterium and ¹³C labeled Azithromycin .

HY-40354AS

Tofacitinib-d3 citrate
Tofacitinib-d₃ (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

HY-12008S

Erlotinib-d6 hydrochloride
Erlotinib-d₆ hydrochloride a deuterium labeled Erlotinib Hydrochloride. Erlotinib Hydrochloride inhibits purified EGFR kinase with an IC₅₀ of 2 nM . Erlotinib-d6 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-40354S

Tofacitinib-13C3
Tofacitinib- ¹³C₃ is the ¹³C-labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

HY-40354S2

Tofacitinib-13C,d3
Tofacitinib- ¹³C,d₃ (Tasocitinib- ¹³C,d₃) is ¹³C labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-40354S1

Tofacitinib-13C3,15N
Tofacitinib- ¹³C₃, ¹⁵N (Tasocitinib- ¹³C₃, ¹⁵N) is ¹³C and ¹⁵N labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-50896S1

Erlotinib-13C6
Erlotinib- ¹³C₆ is a ¹³C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC₅₀ of 2 nM for human EGFR .

HY-150665S

N-Dansyl-d6 1,4-diaminobutane, 97% (CP)
N-Dansyl-d₆ 1,4-diaminobutane, 97% (CP) is the deuterium labeled N-Dansyl 1,4-diaminobutane, 97% (CP) .

HY-W653875

Azithromycin-d5
Azithromycin-d₅ (CP-62993-d₅) is the deuterium labeled Azithromycin (CP-62993) (HY-17506) . Azithromycin is a macrolide antibiotic useful for thestudy of a number of bacterial infections .

HY-17506S

Azithromycin-d3
Azithromycin-d₃ is the deuterium labeled Azithromycin. Azithromycin (CP-62993) is a macrolide antibiotic useful for the treatment of a number of bacterial infections .

HY-B0501S

Danofloxacin-d3 mesylate
Danofloxacin-d₃ (mesylate) is the deuterium labeled Danofloxacin mesylate. Danofloxacin mesylate (CP 76136-27) is a fluoroquinolone antibacterial for veterinary use.

HY-B0334AS

Sulbactam-d5 sodium
Sulbactam-d₅ (sodium) is the deuterium labeled Sulbactam sodium. Sulbactam (CP45899) sodium is a competitive, irreversible beta-lactamase inhibitor. Sulbactam sodium shows antimicrobial activity against multidrug-resistant (MDR) acinetobacter calcoaceticus--Acinetobacter baumannii (Acb) complex .

HY-B0254S

Glipizide-d11
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .

HY-13010S

Laquinimod-d5

Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-10019AS1

Varenicline-d4 hydrochloride

Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

HY-113421S

Linoleoyl ethanolamide-d4

Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide . Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks